Alterity Therapeutics, a biotechnology company, announced new data on its lead drug candidate ATH434 at the World Orphan Drug Congress USA 2024 on April 29, 2024. The data presented suggests ATH434's potential as an iron chaperone to treat Friedreich’s Ataxia, a rare neurodegenerative disease. Unlike traditional iron chelators, ATH434 is designed to redistribute iron within the body rather than remove it. This could address the pathology of diseases like Friedreich’s Ataxia by reducing labile iron levels and slowing disease progression. The study, presented by Ashley Pall from Wayne State University, highlighted ATH434's unique iron-targeting properties and its lower affinity for ferric iron compared to traditional chelators. ATH434 has completed Phase 1 studies and is currently in two Phase 2 clinical trials for Multiple System Atrophy (MSA), with Orphan drug designation granted by the U.S. FDA and the European Commission for MSA treatment. The announcement was authorized by CEO David Stamler and the poster presentation is available on Alterity's website.

Alterity Therapeutics, a biotechnology company, announced new data on its lead drug candidate ATH434 at the World Orphan Drug Congress USA 2024 on April 29, 2024. The data presented suggests ATH434's potential as an iron chaperone to treat Friedreich’s Ataxia, a rare neurodegenerative disease. Unlike traditional iron chelators, ATH434 is designed to redistribute iron within the body rather than remove it. This could address the pathology of diseases like Friedreich’s Ataxia by reducing labile iron levels and slowing disease progression. The study, presented by Ashley Pall from Wayne State University, highlighted ATH434's unique iron-targeting properties and its lower affinity for ferric iron compared to traditional chelators. ATH434 has completed Phase 1 studies and is currently in two Phase 2 clinical trials for Multiple System Atrophy (MSA), with Orphan drug designation granted by the U.S. FDA and the European Commission for MSA treatment. The announcement was authorized by CEO David Stamler and the poster presentation is available on Alterity's website.